Loading…
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer
The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patien...
Saved in:
| Published in: | British journal of cancer 1998-06, Vol.77 (11), p.2008-2011 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c446t-fcee9d5c63b8f14d1294d13d761838d75c35945636f118ceec7a7e8afa7047e3 |
|---|---|
| cites | |
| container_end_page | 2011 |
| container_issue | 11 |
| container_start_page | 2008 |
| container_title | British journal of cancer |
| container_volume | 77 |
| creator | Peppercorn, PD Reznek, RH Wilson, P Slevin, ML Gupta, RK |
| description | The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered. |
| doi_str_mv | 10.1038/bjc.1998.333 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2150330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9667683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-fcee9d5c63b8f14d1294d13d761838d75c35945636f118ceec7a7e8afa7047e3</originalsourceid><addsrcrecordid>eNptkUuL2zAUhUWZMpN57Lod0GKWdUaybEveFMr0NRDoJnshy1KiYEtGUgKZPzF_udckhBa60et85150D0KfKFlSwsRzt9NL2rZiyRj7gBa0ZmVBRcmv0IIQwgvSluQG3aa0g2tLBL9G123T8EawBXr_ZsbgU44qu-BxsHhrJjhrnLJROSSXcHfEOozTPpvo3kyPcxjDJqppe8TO45k2PiccjTbu4PwG14Ud9iGGfVTaDUWn0uzaGvAcsQ0Rq_6gvIZHHYYAvqwGrOeXeI8-WjUk83De79D6x_f1y69i9fvn68vXVaGrqsmF1ca0fa0b1glLq56WLSys5w0VTPS81qxuq7phjaVUAKy54kYoqzipuGF36Mup7LTvRtNr-EBUg5yiG1U8yqCc_Ffxbis34SBLWhPGCBT4fCqgY0gpGnvxUiLnWCTEIudYJMQC-OPf_S7wOQfQn866SloNNsIwXLpgZVmXnFDAihOWQPEbE-UOhuxhUP9v-weiqqpM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer</title><source>PubMed Central</source><creator>Peppercorn, PD ; Reznek, RH ; Wilson, P ; Slevin, ML ; Gupta, RK</creator><creatorcontrib>Peppercorn, PD ; Reznek, RH ; Wilson, P ; Slevin, ML ; Gupta, RK</creatorcontrib><description>The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1998.333</identifier><identifier>PMID: 9667683</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; clinical-oncology ; Colorectal Neoplasms - diagnostic imaging ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - physiopathology ; Drug Resistance ; Drug toxicity and drugs side effects treatment ; Epidemiology ; Fatty Liver - diagnostic imaging ; Female ; Fluorouracil - therapeutic use ; Humans ; Leucovorin - therapeutic use ; Liver - physiopathology ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Oncology ; Pharmacology. Drug treatments ; Tomography, X-Ray Computed ; Toxicity: digestive system</subject><ispartof>British journal of cancer, 1998-06, Vol.77 (11), p.2008-2011</ispartof><rights>Cancer Research Campaign 1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-fcee9d5c63b8f14d1294d13d761838d75c35945636f118ceec7a7e8afa7047e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150330/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150330/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2252701$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9667683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peppercorn, PD</creatorcontrib><creatorcontrib>Reznek, RH</creatorcontrib><creatorcontrib>Wilson, P</creatorcontrib><creatorcontrib>Slevin, ML</creatorcontrib><creatorcontrib>Gupta, RK</creatorcontrib><title>Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered.</description><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>clinical-oncology</subject><subject>Colorectal Neoplasms - diagnostic imaging</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - physiopathology</subject><subject>Drug Resistance</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epidemiology</subject><subject>Fatty Liver - diagnostic imaging</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Leucovorin - therapeutic use</subject><subject>Liver - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tomography, X-Ray Computed</subject><subject>Toxicity: digestive system</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNptkUuL2zAUhUWZMpN57Lod0GKWdUaybEveFMr0NRDoJnshy1KiYEtGUgKZPzF_udckhBa60et85150D0KfKFlSwsRzt9NL2rZiyRj7gBa0ZmVBRcmv0IIQwgvSluQG3aa0g2tLBL9G123T8EawBXr_ZsbgU44qu-BxsHhrJjhrnLJROSSXcHfEOozTPpvo3kyPcxjDJqppe8TO45k2PiccjTbu4PwG14Ud9iGGfVTaDUWn0uzaGvAcsQ0Rq_6gvIZHHYYAvqwGrOeXeI8-WjUk83De79D6x_f1y69i9fvn68vXVaGrqsmF1ca0fa0b1glLq56WLSys5w0VTPS81qxuq7phjaVUAKy54kYoqzipuGF36Mup7LTvRtNr-EBUg5yiG1U8yqCc_Ffxbis34SBLWhPGCBT4fCqgY0gpGnvxUiLnWCTEIudYJMQC-OPf_S7wOQfQn866SloNNsIwXLpgZVmXnFDAihOWQPEbE-UOhuxhUP9v-weiqqpM</recordid><startdate>19980601</startdate><enddate>19980601</enddate><creator>Peppercorn, PD</creator><creator>Reznek, RH</creator><creator>Wilson, P</creator><creator>Slevin, ML</creator><creator>Gupta, RK</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19980601</creationdate><title>Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer</title><author>Peppercorn, PD ; Reznek, RH ; Wilson, P ; Slevin, ML ; Gupta, RK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-fcee9d5c63b8f14d1294d13d761838d75c35945636f118ceec7a7e8afa7047e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>clinical-oncology</topic><topic>Colorectal Neoplasms - diagnostic imaging</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - physiopathology</topic><topic>Drug Resistance</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epidemiology</topic><topic>Fatty Liver - diagnostic imaging</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Leucovorin - therapeutic use</topic><topic>Liver - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tomography, X-Ray Computed</topic><topic>Toxicity: digestive system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peppercorn, PD</creatorcontrib><creatorcontrib>Reznek, RH</creatorcontrib><creatorcontrib>Wilson, P</creatorcontrib><creatorcontrib>Slevin, ML</creatorcontrib><creatorcontrib>Gupta, RK</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peppercorn, PD</au><au>Reznek, RH</au><au>Wilson, P</au><au>Slevin, ML</au><au>Gupta, RK</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1998-06-01</date><risdate>1998</risdate><volume>77</volume><issue>11</issue><spage>2008</spage><epage>2011</epage><pages>2008-2011</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>9667683</pmid><doi>10.1038/bjc.1998.333</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1998-06, Vol.77 (11), p.2008-2011 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2150330 |
| source | PubMed Central |
| subjects | Adult Aged Antimetabolites, Antineoplastic - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research clinical-oncology Colorectal Neoplasms - diagnostic imaging Colorectal Neoplasms - drug therapy Colorectal Neoplasms - physiopathology Drug Resistance Drug toxicity and drugs side effects treatment Epidemiology Fatty Liver - diagnostic imaging Female Fluorouracil - therapeutic use Humans Leucovorin - therapeutic use Liver - physiopathology Male Medical sciences Middle Aged Molecular Medicine Oncology Pharmacology. Drug treatments Tomography, X-Ray Computed Toxicity: digestive system |
| title | Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A57%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Demonstration%20of%20hepatic%20steatosis%20by%20computerized%20tomography%20in%20patients%20receiving%205-fluorouracil-based%20therapy%20for%20advanced%20colorectal%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Peppercorn,%20PD&rft.date=1998-06-01&rft.volume=77&rft.issue=11&rft.spage=2008&rft.epage=2011&rft.pages=2008-2011&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1998.333&rft_dat=%3Cpubmed_cross%3E9667683%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-fcee9d5c63b8f14d1294d13d761838d75c35945636f118ceec7a7e8afa7047e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/9667683&rfr_iscdi=true |